Peter DiLaura was named President and CEO of Second Genome in November 2010. Prior to Second Genome, Peter was the Senior Vice President of Products and Marketing at Ingenuity Systems, where he was responsible for a variety of roles on the senior management team including business development, global sales and marketing, and corporate strategy. Prior to Ingenuity, Peter held roles at Chemdex/Ventro and IBM. Peter began his career in life sciences as a strategy consultant to the pharmaceutical and biotechnology industries in the New York office of The Wilkerson Group. Peter received a BS in Economics from the Wharton School at the University of Pennsylvania.

Karim Dabbagh leads the R&D organization at Second Genome. Prior to that, he led the immunoregulation department at Pfizer, an R&D group focused on innovative approaches to elicit homeostatic immune responses, including microbiome research, for the treatment of immune related disorders. At Pfizer, he also led external R&D innovation for autoimmune and inflammatory diseases. Past responsibilities include founding Modus BioMedicine, a start-up biotechnology company focused on treatments for transplantation and autoimmune disease, as well as spending nine years at Roche Pharmaceuticals in Inflammation Discovery Research. Dr. Dabbagh received his PhD in biochemistry from University College, London and his BS in biotechnology from the Imperial College of Science, Technology, and Medicine in London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on elucidating the role played by the microbiome in the hygiene hypothesis.

Mohan Iyer is Chief Business Officer of Second Genome.  He started his career as a biochemical engineer at Genentech in the mid-80s, when the biotech industry itself was comprised of just a couple of start-ups.  In a career spanning almost 30 years in biotech, he has held various executive level positions in both technical and business functions at several venture-backed companies with a focus on translating genomics, diagnostics, and personalized medicine. Outside of operating biotech companies, he has also been an investment banker and a management consultant, which further expands his industry perspective. He holds a BS in Chemical Engineering (Tennessee), an MS in Biomedical Engineering (Duke) and an MBA (Yale).

Todd DeSantis is Second Genome Co-founder and Senior Director of Bioinformatics. Todd has 17 years of experience designing and implementing bioinformatics solutions for analyzing microbial community dynamics.  At Lawrence Berkeley National Laboratory he led the development of novel microbiome assays and analysis pipelines as a Molecular Microbial Ecology Software Developer. He is the chief architect of GreengenesTM, an international effort to catalog global microbial diversity that provides microbial ecologists with reference databases for DNA quality assessment, alignment and classification. Todd also served as an analyst for the NIH Human Microbiome Project and has published over 60 scientific papers.  At Second Genome, he manages all informatics work including identifying and recruiting microbiome scientist leaders, integration of multi-omics pipelines, cloud deployment for big-data analytics, and therapeutic pathway discovery.